Coya Therapeutics, Inc. announced the appointment of Dr. Fred Grossman to its senior management team as President and Chief Medical Officer. Dr. Grossman will succeed Dr. Adrian Hepner in this role, effective July 17th, 2023, and will leverage his over two decades of clinical development expertise to guide and oversee all of Coya’s development programs, including its lead asset, COYA 302, for the treatment of Amyotrophic Lateral Sclerosis (ALS). Prior to joining Coya, Dr. Grossman held executive positions at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Sunovion.

He also served as President and Chief Medical Officer at Glenmark Pharmaceuticals, (BSE: 532296), a $1.5 Billion per annum global pharmaceutical company based in India, overseeing development of the entire pipeline including generics, complex generics including 505(b)(2) candidates, and next-generation biologics (including bi-specific antibodies). He also previously served as Chief Medical Officer at Mesoblast, Inc., developing allogeneic cellular therapies for inflammatory diseases.